OPKO Health Inc :Pfizer And Opko’S Once-Weekly Ngenla™ (Somatrogon) Injection Receives Marketing Authorization In European Union For Treatment Of Pediatric Growth Hormone Deficiency.Opko Health Inc - Marketing Authorization Of Ngenla Is Valid In All Eu Member States As Well As Iceland, Norway And Liechtenstein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments